Kezar Life Sciences KZR 深 沪
等待开盘 05-20 09:30:00 美东时间
7.29
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 7.29
- 总市值 5385.63万
- 52周最高 7.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.5334
- 委 比 0.00%
- 总股本 738.77万
- 历史最高 363.27
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.5334
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kezar Life Sciences Acquired by Aurinia, Delisted From Nasdaq
An update from Kezar Life Sciences ( ($KZR) ) is now available. On May 11, 2026...
05-11 22:03
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Au...
05-11 21:59
Kezar Life Sciences Announces Major Executive Leadership Changes
Kezar Life Sciences ( ($KZR) ) has issued an announcement. On April 1, 2026, Ke...
04-04 05:27
Aurinia Pharmaceuticals acquiring Kezar Life Sciences
Aurinia Pharmaceuticals (AUPH) is acquiring Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one contingent value right. The CVR gives the shareholder the right to re...
03-30 22:06
Aurinia to buy Kezar for USD 6.96 per share plus CVR
Aurinia to buy Kezar for USD 6.96 per share plus CVR Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.96 per share in cash. Deal includes a non-transferable contingent value right tied to zetomipzomib development milestones and select asset-related proceeds. Aurinia plans to l
03-30 20:34
Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
03-30 20:04
Enodia Therapeutics Acquires Kezar Life Sciences Preclinical Assets For Up to $127M Plus Royalties
Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory
03-12 21:06
Kezar Life Sciences Q3 EPS $(1.53) Beats $(2.08) Estimate
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(2.08) by 26.3 percent. This is a 44.96 percent increase over losses of $(2.78) per share from
2025-11-13 05:33
Kezar Life Sciences Announces Two Presentations From Completed Phase 2a PORTOLA Clinical Trial In Patients With Autoimmune Hepatitis At 2025 AASLD
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the
2025-11-07 20:08
Kezar Life Sciences Reports Positive Phase 2 Results for Zetomipzomib in Autoimmune Hepatitis and Lupus Nephritis
Kezar Life Sciences Inc. has announced upcoming presentations of clinical trial data for its investigational drug zetomipzomib at major medical conferences in November 2025. Data from the completed Ph...
2025-11-07 20:02
